Search Results for:
-
Women Leaders in Biotech: 'Walls Are Coming Down'
Jessica Flechtner For Jessica Flechtner, her current role as vice president of research at Genocea Biosciences Inc., of Cambridge, Mass., is a "perfect fit that fell into my lapBy Catherine Shaffer | BioWorld Today | Wednesday, April 17, 2013 -
Armetheon Seeks to Repurpose Stalled Late-Stage Compounds
Company principals knew the compound intimately, since two of Armetheon's co-founders – Pascal Druzgala, senior vice president of research and chief scientific officer, and Peter Milner, executive chairman – had formed ARYx in the late 1990sBy Marie Powers | BioWorld Today | Monday, April 15, 2013 -
Roche, Isis Join 'Hunt' for Brain Cures in $392M Partnership
According to Frank Bennett, senior vice president of research for Isis, those drugs are not disease-modifying optionsBy Catherine Shaffer | BioWorld Today | Tuesday, April 9, 2013 -
Appointments and Advancements
Avaxia Biologics Inc., of Lexington, Mass., added Deborah S. Hartman vice president of researchBioWorld Today | Monday, April 1, 2013 -
Appointments and Advancements
Ironwood Pharmaceuticals Inc., of Cambridge, Mass., named Mark Currie senior vice president, chief scientific officer and president of research and developmentBioWorld Today | Tuesday, March 5, 2013 -
Industry-Academic Research Gets $261M Boost in Ireland
We have upped the credibility of those sites within the corporate structure," Mary Shire, UL's vice president of research, told BioWorld InternationalBy Cormac Sheridan | BioWorld International | Wednesday, February 27, 2013 -
Gamida Cell's StemEx Improves Overall Survival in Phase II/III
or Europe. (See BioWorld Today, May 23, 2012.) The StemEx technology, developed by company co-founder Tony Peled, who now serves as chief scientific officer and vice president of research and development, is the first to complete a Phase III study in the transplantation regimen, according to MargolinBy Marie Powers | BioWorld International | Wednesday, February 6, 2013 -
Gamida Cell's StemEx Improves Overall Survival in Phase II/III
or Europe. (See BioWorld Today, May 23, 2012.) The StemEx technology, developed by company co-founder Tony Peled, who now serves as chief scientific officer and vice president of research and development, is the first to complete a Phase III study in the transplantation regimen, according to MargolinBy Marie Powers | BioWorld Today | Tuesday, February 5, 2013 -
Enbrel Drives Amgen Earnings; Company Shoots High for Year
Sean Harper, vice president of research and development, noted that the approach is "fairly standard" with lipid-lowering drugsBy Randy Osborne | BioWorld Today | Friday, January 25, 2013 -
Other News To Note
Also, the compensation committee approved the grant of a stock option to purchase 15,000 shares of common stock and 4,000 restricted stock units to Shripad Bhagwat, a newly hired vice president of researchBioWorld Today | Tuesday, January 22, 2013 -
With Patents, Light Touch Can Be More Useful Than Iron Grip
Sangamo chief scientific officer and vice president of research Philip Gregory told BioWorld Insight that to get the most out of patents, it can be useful to differentiate between therapeutic and research uses – and to avoid digging in one's talons in favor of a lighter touchBy Anette Breindl | BioWorld Insight | Wednesday, December 26, 2012 -
Medivir's Simeprevir Aces Three Phase III HCV Trials
The data that we have from all three studies are very solid and very similar," Charlotte Edenius, executive vice president of research and development at Stockholm, Sweden-based Medivir, told investors during a conference callBy Cormac Sheridan | BioWorld International | Wednesday, December 26, 2012 -
Medivir's Simeprevir Aces Three Phase III HCV Trials
The data that we have from all three studies are very solid and very similar," Charlotte Edenius, executive vice president of research and development at Stockholm, Sweden-based Medivir, told investors during a conference callBy Cormac Sheridan | BioWorld Today | Friday, December 21, 2012 -
MD Anderson, GSK Ink Potential $335M Oncology Drug Pact
Nevertheless, Draetta's experience in pharma and biotech – a decade ago, he also served as co-founder and vice president of research at former drug discovery firm Mitotix Inc. – provided the IACS with a seasoned leader who understood the "milestone-driven" pharma culture that keeps experts from both sides of the table working together until a preclinical compound has proven its mettleBy Marie Powers | BioWorld Today | Monday, December 10, 2012 -
Appointments and Advancements
OthoCyte Corp., a subsidiary of BioTime Inc., of Alameda, Calif., appointed Francois Binette vice president of research and business developmentBioWorld Today | Thursday, November 15, 2012 -
Santarus Makes Phase III HAE, Pharming for Harvest in Acute
which are thromboembolic," said Wendell Wierenga, vice president of research and development of San Diego-based SantarusBy Randy Osborne and Cormac Sheridan | BioWorld International | Wednesday, November 14, 2012 -
Santarus Makes Phase III HAE, Pharming for Harvest in Acute
which are thromboembolic," said Wendell Wierenga, vice president of research and development of San Diego-based SantarusBy Randy Osborne and Cormac Sheridan | BioWorld Today | Thursday, November 8, 2012 -
'Baxter' the Wall: Biogen/Sobi Data Weighed in Hemophilia A
trough levels," said Douglas Williams, vice president of research and development for BiogenBy Randy Osborne | BioWorld International | Wednesday, November 7, 2012 -
'Baxter' the Wall: Biogen/Sobi Data Weighed in Hemophilia A
trough levels," said Douglas Williams, vice president of research and development for BiogenBy Randy Osborne | BioWorld Today | Thursday, November 1, 2012 -
Appointments and Advancements
Synthetic Biologics Inc., of Ann Arbor, Mich., named Andrew Bristol vice president of research and development and Michael Kaleko senior vice president of research and developmentBioWorld Today | Tuesday, October 30, 2012
Category
Current Filters
- xpresident of research
Related Keywords
Categories
- x BioWorld Today (985)
- x BioWorld International (79)
- x BioWorld Genomics Review (47)
- x BioWorld Insight (24)
- x Bio Perspectives (15)
- x Executive Compensation Report (6)
- x State of the Industry Report (3)
- x Biotech Innovations (2)
- x Market-Leading Biotech Drugs (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.